Kiedy wybieram omeprazol, a kiedy famotydynę? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lis 30, 2025
Słowa kluczowe:
famotydyna, omeprazol, refluks żołądkowo-przełykowy, zgaga
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule zostały omówione typowe wskazania do stosowania omeprazolu i famotydyny. Szczególną uwagę zwrócono na kryteria wskazujące na wybór omeprazolu lub na wybór famotydyny.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Caban, M., & Małecka-Wojciesko, E. (2025). Kiedy wybieram omeprazol, a kiedy famotydynę? . Medycyna Faktów , 18(3(68), 426-428. https://doi.org/10.24292/01.MF.0325.14
Numer
Dział
Artykuły
Copyright by Medical Education. All rights reserved.
Bibliografia
1. López-Pintor E, Puig-Moltó M, Lumbreras B. EsReflux Protocol: Epidemiological Study of Heartburn and Reflux-like Symptoms in Spanish Community Pharmacies. Int J Environ Res Public Health. 2022; 19: 9807. http://doi.org/10.3390/ijerph19169807.
2. Boura F, Al-Tabakha MM, Hassan N et al. Community pharmacists’ response to complaints of gastroesophageal reflux: A simulated patient study in the Northern United Arab Emirates. PLoS One. 2023; 18: e0279922. http://doi.org/10.1371/journal.pone.0279922.
3. Świdnicka-Siergiejko AK, Marek T, Waśko-Czopnik D et al. Diagnostic and therapeutic management in gastroesophageal reflux disease: consensus of the Polish Society of Gastroenterology. Pol Arch Intern Med. 2022; 132: 16196. http://doi.org/10.20452/pamw.16196.
4. Zubiete-Franco I, Tonks NK. Famotidine increases cellular phospho-tyrosine levels. Biochem Biophys Res Commun. 2024; 734: 150763. http://doi.org/10.1016/j.bbrc.2024.150763.
5. Al Ali HS, Jabbar AS, Neamah NF et al. Long-Term Use of Omeprazole: Effect on Haematological and Biochemical Parameters. Acta Med Indones. 2022; 54: 585-94.
6. Waśko-Czopnik D. 4 profile pacjentów, w leczeniu których wybieram famotydynę. Medycyna Faktów. 2023; 16: 43-5. http://doi.org/10.24292/01.MF.0123.07.
7. Zou S, Ouyang M, Cheng Q et al. Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. Pharmacotherapy. 2024; 44: 171-83. http://doi.org/10.1002/phar.2899.
8. Sawaid IO, Samson AO. Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence. J Clin Med. 2024; 13: 1970. http://doi.org/10.3390/jcm13071970.
9. McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014; 5: 57-62. http://doi.org/10.4292/wjgpt.v5.i2.57.
2. Boura F, Al-Tabakha MM, Hassan N et al. Community pharmacists’ response to complaints of gastroesophageal reflux: A simulated patient study in the Northern United Arab Emirates. PLoS One. 2023; 18: e0279922. http://doi.org/10.1371/journal.pone.0279922.
3. Świdnicka-Siergiejko AK, Marek T, Waśko-Czopnik D et al. Diagnostic and therapeutic management in gastroesophageal reflux disease: consensus of the Polish Society of Gastroenterology. Pol Arch Intern Med. 2022; 132: 16196. http://doi.org/10.20452/pamw.16196.
4. Zubiete-Franco I, Tonks NK. Famotidine increases cellular phospho-tyrosine levels. Biochem Biophys Res Commun. 2024; 734: 150763. http://doi.org/10.1016/j.bbrc.2024.150763.
5. Al Ali HS, Jabbar AS, Neamah NF et al. Long-Term Use of Omeprazole: Effect on Haematological and Biochemical Parameters. Acta Med Indones. 2022; 54: 585-94.
6. Waśko-Czopnik D. 4 profile pacjentów, w leczeniu których wybieram famotydynę. Medycyna Faktów. 2023; 16: 43-5. http://doi.org/10.24292/01.MF.0123.07.
7. Zou S, Ouyang M, Cheng Q et al. Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. Pharmacotherapy. 2024; 44: 171-83. http://doi.org/10.1002/phar.2899.
8. Sawaid IO, Samson AO. Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence. J Clin Med. 2024; 13: 1970. http://doi.org/10.3390/jcm13071970.
9. McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014; 5: 57-62. http://doi.org/10.4292/wjgpt.v5.i2.57.